Concord Biotech

    CONCORDBIO
    Pharma
    ₹561.00
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹11,738 Cr

    P/E
    41.99
    Day range
    ₹545.90 – ₹566.30
    52-week range
    ₹493.50 – ₹807.50
    Volume
    5.70 L
    Open
    ₹546.80
    Prev close
    ₹554.80

    Latest results · Q2 FY27(consolidated)Revenue ₹309 Cr+25.1%Profit ₹70 Cr+10.3%Margin 22.5%YoY vs the same quarter last year

    No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.

    Research profile

    Composite 44 / 100

    Factor percentiles

    Value41
    Quality64
    Momentum32
    Low volatility39

    Derived metrics

    Earn. yield
    2.4%
    Graham no.
    ₹169.47
    vs Graham
    -69.8%
    ROE ÷ P/B
    2.3%
    12-1 mom.
    -7.0%
    Return / vol
    -0.52
    Magic Formula
    #380
    Piotroski
    3/6
    FCF yield
    1.5%
    PEG
    4.07

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 68 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.49 L Cr40.955.0314.8%21.0%29.0%0.04+11.9%
    Divi's LaboratoriesDIVISLAB₹2.93 L Cr87.1916.8816.2%22.0%43.0%0.00+35.4%
    Torrent PharmaTORNTPHARM₹1.75 L Cr77.889.6726.8%15.0%33.0%0.77+50.8%
    Apollo HospitalsAPOLLOHOSP₹1.27 L Cr56.4011.5522.6%17.0%16.0%0.77+23.0%
    Laurus LabsLAURUSLABS₹1.25 L Cr93.7219.8218.2%18.0%34.0%0.43+33.5%
    Zydus LifesciencesZYDUSLIFE₹1.20 L Cr28.724.3220.1%21.0%24.0%0.50+29.2%
    Dr. Reddy's LabsDRREDDY₹1.17 L Cr41.632.9711.6%13.0%20.0%0.19-1.5%
    Concord BiotechCONCORDBIO₹11,738 Cr41.995.9913.5%17.0%34.0%0.00+25.1%
    Sector median₹24,603 Cr43.685.4615.1%17.0%24.0%0.17+22.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 2h ago

    Headlines about Concord Biotech from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.

    Key metrics

    P/E (TTM)
    41.2
    Price / Book
    5.66
    ROE (FY26)
    13.5%
    ROCE (latest year)
    17%
    Dividend yield
    0.67%

    Moving averages (NSE)

    20-day
    ₹617.19
    Price below
    50-day
    ₹673.4
    Price below
    200-day
    ₹631.34
    Price below

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +7.3%
    Profit 3Y CAGR
    +2.6%
    Revenue YoY (Sep 2026)
    +25.1%
    Profit YoY (Sep 2026)
    +11.1%
    Operating margin
    34.0%
    Net margin
    22.7%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    0 Cr200 Cr400 Cr600 Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Sep 20260%25%50%

    Who owns the company

    % of equity by quarter, latest Nov 2026

    Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '26Nov '260%25%50%75%100%
    • Promoter
    • Public
    • DII
    • FII

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2018 (S)Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-200 Cr0 Cr200 Cr400 Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY16FY18FY19FY20FY21FY22FY23FY24FY25FY260%10%20%30%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr1K Cr2K Cr3K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2019 (S)Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 20260x0.5x1x

    Dividends per share

    ₹ by fiscal year of the ex-date; the latest year runs to date. Not adjusted for the bonus of 4 Nov 2026: earlier bars are per pre-bonus share.

    FY26FY27₹0₹5₹10₹15

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales241319216310244430204247278326257309
    YoY Sales growth——————-5-20—-24——
    Expenses135187135176146241143159179208175205
    Operating Profit106132811349818961889811882104
    OPM %44%41%38%43%40%44%30%36%35%36%32%34%
    Other Income1111121017915167151410
    Interest000000000000
    Depreciation141413131315181819201818
    Profit before tax103129801301011845986861147895
    Tax %25%26%25%27%25%24%25%26%26%22%26%27%
    Net Profit7895609676140446364885870
    EPS in Rs₹3.71₹4.54₹2.85₹4.58₹3.63₹6.71₹2.11₹3.04₹3.08₹4.24₹2.80₹3.38

    From company filings, updated 19 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days159

    +54 days since Mar 2021

    Inventory Days485

    -18 days since Mar 2021

    Days Payable151

    -1 days since Mar 2021

    Cash Conversion Cycle493

    +37 days since Mar 2021

    Working Capital Days230

    +53 days since Mar 2021

    Strengths, risks & growth

    Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology. [1]

    Strengths

    • Company has reduced debt.
    • Company is almost debt free.
    • Company has been maintaining a healthy dividend payout of 28.2%

    Risks

    • The company has delivered a poor sales growth of 11.3% over past five years.
    • Company has high debtors of 159 days.

    Compounded Sales Growth

    10 Years
    —
    5 Years
    +11%
    3 Years
    +7%
    TTM
    +4%

    Compounded Profit Growth

    10 Years
    —
    5 Years
    +1%
    3 Years
    +1%
    TTM
    -12%

    Stock Price CAGR

    10 Years
    —
    5 Years
    —
    3 Years
    -3%
    1 Year
    -23%

    Return on Equity

    10 Years
    —
    5 Years
    +18%
    3 Years
    +18%
    Last Year
    +13%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderMar 2026Jun 2026Sept 2026Nov 2026Change
    Promoter44.08%44.08%44.09%44.09%0.00 pp
    FII7.79%7.53%7.28%7.33%+0.05 pp
    DII9.22%9.37%10.95%11.02%+0.07 pp
    Public38.90%39.04%37.68%37.58%-0.10 pp

    Filed with NSE for Nov 2026: promoters 44.09%, public 55.91%

    Analysts & fund holdings

    80%
    80% recommend buy
    5 analysts cover the stock
    Valuation vs Pharmaceuticals
    P/E42.0 vs 45.2
    Sector P/B6.05

    Who holds the shares, quarter by quarter

    Mutual funds 5.85% (+0.01 pp)
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    Sept 26
    Nov 26
    • Promoters44.1%
    • Foreign institutions7.3%
    • Mutual funds5.8%
    • Insurance4.3%
    • Other domestic institutions0.9%
    • Retail6.5%
    • Others31.0%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    DSP Small Cap Fund2.68%1.61%+0.68 pp
    SBI Healthcare Opp Fund0.95%1.97%+0.08 pp
    DSP Healthcare Fund0.75%2.46%+0.52 pp
    Edelweiss Small Cap Fund0.58%1.05%-0.13 pp
    Altiva Equity Ex-Top 100 Long-Short Fund0.22%1.75%-0.59 pp

    Scorecard

    Performance
    Low
    Valuation
    High
    Growth
    Low
    Profitability
    High
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.

    Risk & trend

    From 292 daily sessions to 18 Nov 2026. Adjusted for 1 corporate action.

    Computed

    Risk

    Volatility (1Y)
    42.3%
    Downside volatility
    38.9%
    Worst 5% of days
    4.1%
    Average of that tail
    5.4%
    Max drawdown (1Y)
    40.1%
    Below its peak
    33.8%

    Against the market

    Beta vs Nifty 50
    0.90
    Correlation
    0.29
    Relative strength (3M)
    -29.8%
    ATR (14)
    5.4%

    Return

    Return 1M
    -16.2%
    Return 3M
    -25.9%
    Return 6M
    -0.3%
    Return 1Y
    -22.0%
    vs 200-day average
    -11.1%

    Momentum

    RSI (14)
    36.5
    MACD histogram
    -4.59
    Stochastic %K
    10.9
    ADX (14)
    21.5
    +DI / −DI
    18.5 / 33.5
    Money flow index
    26.1

    Participation

    Delivery (20d avg)
    43.9%
    vs its 60-day baseline
    -2.2 pts
    Volume vs 20-day
    +1.0σ
    Close vs day's VWAP
    +0.2%
    52-week position
    16 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 30 Sept 2026.

    Computed

    Piotroski F-Score

    3 of 6 tested

    • Return on assets positive — passed
    • Operating cash flow positive — not testableno cash flow statement for this period
    • Return on assets improving — failed
    • Cash flow exceeds profit — not testableneeds cash flow and profit against assets
    • Debt to assets falling — passed
    • Current ratio improving — failed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — failed
    • Asset turnover improving — passed
    Free cash flow
    ₹172 Cr
    FCF yield
    1.5%
    Cash conversion
    1.03
    Accruals ratio
    -0.003
    Net debt
    -₹6 Cr
    Net debt / equity
    -0.00
    EV / sales
    10.02
    PEG
    4.07
    Capex intensity
    9.0%
    Revenue CAGR
    -19.7%
    Profit CAGR
    -37.3%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Corporate actions

    • bonus
      Not available — not reported in this filing

      Bonus 1:1

      4 Nov 2026
      ex-date
    • dividend
      ₹7.55

      Dividend - Rs 7.55 Per Share

      24 Jul 2026
      ex-date
    • dividend
      ₹10.70

      Dividend - Rs 10.70 Per Share

      3 Sept 2025
      ex-date
    • dividend
      ₹8.75

      Dividend - Rs 8.75 Per Share

      21 Jun 2024
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      21 Jun 2024
      ex-date

    Company announcements

    Company Update
    Announcement under Regulation 30 (LODR)-Allotment

    Intimation of allotment of Bonus equity Shares

    Company Update
    Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    Transcript of Q2 - FY27 Earnings call held on October 28, 2026

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    Earning Call Recording- For the Second Quarter and half year ended on September 30, 2026

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation of Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 to be held on 03rd and 4th November, 2026.

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Press release - For the Second quarter and half year ended on September 30, 2026

    Company Update
    Announcement under Regulation 30 (LODR)-Investor Presentation

    Investor's presentation on unaudited standalone and consolidated financial results for the second quarter and half year ended on September 30, 2026

    Corp. Action
    Intimation Of Record Date For Issuance Of Bonus Equity Shares - November 04, 2026

    The Board of Directors at its meeting held on October 27, 2026 has fixed Wednesday, November 04, 2026 as record date for issuance of Bonus equity shares in the ratio of 1:1.

    Result
    Unaudited Standalone And Consolidated Financial Results For The Second Quarter And Half Year Ended On September 30, 2026.

    Unaudited Standalone and Consolidated Financial Results for the second quarter and half year ended on September 30, 2026.

    Board Meeting
    Board Meeting Outcome for Meeting Held Today I.E. Tuesday, October 27, 2026 - Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('Listing Regulations') As Amended From Time To Time.

    The Board of Directors of the Company, at its meeting held today i.e. Tuesday, October 27, 2026, has inter-alia considered and approved the Un-audited financial results for the quarter ....

    AGM/EGM
    Shareholder Meeting / Postal Ballot-Scrutinizer"s Report

    Submission of Scrutinizer's report and Voting Results of Postal Ballot dated September 23, 2026

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Earnings Call Invite for the operational and financial performance of the Company for the Quarter and half year ended on September 30, 2026

    Board MeetingPrice-sensitive
    Board Meeting Intimation for Meeting To Be Held On Tuesday, October 27, 2026, Pursuant To Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

    Concord Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2026 ,inter alia, to consider and approve unaudited Standalone and Consolidated ....

    Company Update
    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    In compliance with regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, we furnish herewith certificate received from RTA of the Company.

    Insider Trading / SAST
    Closure of Trading Window

    Pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time and as per the Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading ....

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Newspaper advertisement for Notice of Postal Ballot dated September 23, 2026 and Remote E-Voting Information

    Filed with BSE (scrip 543960); the last 45 days. Documents open at bseindia.com.

    Documents

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 28 Oct 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Concord Biotech: common questions

    Answered from the figures on this page.

    Concord Biotech last traded at ₹561.00 (NSE, as of 18 Nov 2026). The last session moved it up 1.12%.

    Concord Biotech is valued at about ₹11,738 crore (NSE, as of 18 Nov 2026).

    Concord Biotech trades at a price-to-earnings ratio of 41.99 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Concord Biotech has traded between ₹493.50 and ₹807.50 over the past 52 weeks, to 18 Nov 2026. It is currently 21% of the way up that range.

    Concord Biotech (CONCORDBIO) is classified under Pharma on this site's screener.